{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:37:12Z","timestamp":1778553432090,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2012,6,25]],"date-time":"2012-06-25T00:00:00Z","timestamp":1340582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2012,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tight control of intraocular pressure (IOP) is still the only therapeutic approach available for the treatment of primary open angle glaucoma (POAG). However, some patients do not respond adequately to hypotonising drugs, and despite multiple drug combinations they cannot reach their target IOP. Forskolin is a natural compound that has already shown efficacy in IOP reduction following topical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the effects on the IOP of a food supplement containing forskolin and rutin when administered to POAG patients under maximum tolerated medical therapy (MTMT) and on a waiting list for filtrating surgery to further decrease their IOP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The design of the study was open and case-controlled. Ninety-seven (52 in the treatment group, and 45 in the reference group) patients were enrolled in 8 different glaucoma centers in Italy, all under MTMT and with IOP enrollment values above their target pressure. During the 30 days before surgery, patients in the treatment group were prescribed 2 tablets per day of a food supplement containing rutin and forskolin in addition to their usual topical drug treatment. Their IOP values were measured at 3 time points during the day, at enrollment and once a week until surgery. Control patients continued only with their normal topical therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All patients in the treatment group, independently of the combination drug therapy that they were taking, showed a further 10% decrease (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.01) of their IOP, starting from 1 week after introduction of the oral supplement and lasting until the last evaluation before surgery. This decrease was more evident (15% of the enrollment value;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.01) in those subjects with high (IOP\u226521\u2009mmHg) enrollment values rather than in those with low (IOP&lt;21) enrollment values (9%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.01). On the contrary, IOP values in the control group remained stable from the beginning to the end of the observation period, independently of their enrollment values.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Forskolin and rutin given as oral treatment appear to contribute to a better control and a further small reduction of IOP in patients who were poorly responsive to multitherapy treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2012.0021","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T01:51:49Z","timestamp":1340761909000},"page":"536-541","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":44,"title":["Oral Administration of Forskolin and Rutin Contributes to Intraocular Pressure Control in Primary Open Angle Glaucoma Patients Under Maximum Tolerated Medical Therapy"],"prefix":"10.1177","volume":"28","author":[{"given":"Michele","family":"Vetrugno","sequence":"first","affiliation":[{"name":"University of Bari","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio G.","family":"Uva","sequence":"additional","affiliation":[{"name":"University of Catania","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[{"name":"University of Foggia","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Iester","sequence":"additional","affiliation":[{"name":"University of Genoa","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ciancaglini","sequence":"additional","affiliation":[{"name":"University of L'Aquila","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Brusini","sequence":"additional","affiliation":[{"name":"Hospital of Udine","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Centofanti","sequence":"additional","affiliation":[{"name":"UOSD Glaucoma University of Rome Tor Vergata\u2013IRCCS Fondazione Bietti","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca M.","family":"Rossetti","sequence":"additional","affiliation":[{"name":"University of Milano at the San Paolo Hospital","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,6,25]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.53049"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.007"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3280895aea"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767050-00006"},{"issue":"1","key":"e_1_3_4_6_2","first-page":"S15","article-title":"Disease progression and the need for neuroprotection in glaucoma management","volume":"14","author":"Varma R.","year":"2008","unstructured":"Varma R., , Peeples P., , Walt J.G., , Bramley T.J. Disease progression and the need for neuroprotection in glaucoma management. Am. J. Manag. Care., 14,1 Suppl:S15\u2013S19. 2008.","journal-title":"Am. J. Manag. Care."},{"key":"e_1_3_4_7_2","first-page":"35","article-title":"Currents on target intraocular pressure and intraocular pressure fluctuations in glaucoma management","volume":"308","author":"Detry-Morel M.","year":"2008","unstructured":"Detry-Morel M. Currents on target intraocular pressure and intraocular pressure fluctuations in glaucoma management. Bull. Soc. Belge. Ophtalmol., 308:35\u201343. 2008.","journal-title":"Bull. Soc. Belge. Ophtalmol."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000067545"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200110001-00026"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-962512"},{"key":"e_1_3_4_11_2","first-page":"201","article-title":"Forskolin: a unique diterpene activator of cyclic AMP-generating systems","volume":"7","author":"Seamon K.B.","year":"1981","unstructured":"Seamon K.B., , Daly J.W. Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J. Cyclic Nucleotide Res., 7:201\u2013224. 1981.","journal-title":"J. Cyclic Nucleotide Res."},{"key":"e_1_3_4_12_2","first-page":"998","article-title":"Expression of adenylate cyclase subtypes II and IV in the human outflow pathway","volume":"41","author":"Zhang X.","year":"2000","unstructured":"Zhang X., , Wang N., , Schroeder A., , Erickson K.A. Expression of adenylate cyclase subtypes II and IV in the human outflow pathway. Invest. Ophthalmol. Vis. Sci., 41:998\u20131005. 2000.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_4_13_2","first-page":"268","article-title":"Forskolin lowers intraocular pressure by reducing aqueous inflow","volume":"25","author":"Caprioli J.","year":"1984","unstructured":"Caprioli J., , Sears M., , Bausher L., , Gregory D., , Mead A. Forskolin lowers intraocular pressure by reducing aqueous inflow. Invest. Ophthalmol. Vis. Sci., 25:268\u2013277. 1984.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_4_14_2","first-page":"283","article-title":"The adenylate cyclase receptor complex and aqueous humor formation","volume":"57","author":"Caprioli J.","year":"1984","unstructured":"Caprioli J., , Sears M. The adenylate cyclase receptor complex and aqueous humor formation. Yale J. Biol. Med., 57:283\u2013300. 1984.","journal-title":"Yale J. Biol. Med."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2008.0029"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.8.1171"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/307455a0"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/108076804772745446"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/108076804773710777"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2009.03.022"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/147323000603400210"},{"key":"e_1_3_4_22_2","volume-title":"Terminology and Guidelines for Glaucoma","author":"European Glaucoma Society","year":"2008","unstructured":"European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd. European Glaucoma Society: Dogma Srl Ed, 2008.","edition":"3"},{"key":"e_1_3_4_23_2","first-page":"426","article-title":"Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey","volume":"16","author":"Minckler D.S.","year":"1977","unstructured":"Minckler D.S., , Bunt A.H., , Johanson G.W. Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey. Invest. Ophthalmol. Vis. Sci., 16:426\u2013441. 1977.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-1002"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/156652410793937778"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708250200"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cm.20472"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00481.2007"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713680701837067"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2007.10.007"},{"key":"e_1_3_4_31_2","first-page":"1071","article-title":"The possibility of selective Rho-associated kinase (ROCK) inhibitors as a medical treatment for glaucoma","volume":"113","author":"Honjo M.","year":"2009","unstructured":"Honjo M. The possibility of selective Rho-associated kinase (ROCK) inhibitors as a medical treatment for glaucoma. Nihon Ganka Gakkai Zasshi., 113:1071\u20131081. 2009.","journal-title":"Nihon Ganka Gakkai Zasshi."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2005.02.003"},{"key":"e_1_3_4_33_2","first-page":"159","article-title":"Effetti di un integratore alimentare a base di forskolin e rutina sul tono oculare di pazienti glaucomatosi","author":"Cornelio C.","year":"2010","unstructured":"Cornelio C., , Gabaglio A., , Crisigiovanni L., , Perone G. Effetti di un integratore alimentare a base di forskolin e rutina sul tono oculare di pazienti glaucomatosi. Ottica Fisiopatologica., XV:159\u2013164. 2010.","journal-title":"Ottica Fisiopatologica."},{"key":"e_1_3_4_34_2","first-page":"e81","article-title":"Oral administration of an association of forskolin, rutin and vitamins B1 and B2 potentiates the hypotonising effects of pharmacological treatments in POAG patients","volume":"161","author":"Pescosolido N.","year":"2010","unstructured":"Pescosolido N., , Librando A. Oral administration of an association of forskolin, rutin and vitamins B1 and B2 potentiates the hypotonising effects of pharmacological treatments in POAG patients. Clin. Ter., 161:e81\u2013e85. 2010.","journal-title":"Clin. Ter."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200404000-00008"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.06.020"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.07.060"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2012.0021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2012.0021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2012.0021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:37:47Z","timestamp":1777646267000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2012.0021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,25]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10,1]]}},"alternative-id":["10.1089\/jop.2012.0021"],"URL":"https:\/\/doi.org\/10.1089\/jop.2012.0021","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,25]]}}}